EA201600336A2 - MEDICINE FOR PREVENTION AND TREATMENT OF BRAIN DISEASES AND METHOD FOR TREATING BRAIN DISEASES - Google Patents

MEDICINE FOR PREVENTION AND TREATMENT OF BRAIN DISEASES AND METHOD FOR TREATING BRAIN DISEASES

Info

Publication number
EA201600336A2
EA201600336A2 EA201600336A EA201600336A EA201600336A2 EA 201600336 A2 EA201600336 A2 EA 201600336A2 EA 201600336 A EA201600336 A EA 201600336A EA 201600336 A EA201600336 A EA 201600336A EA 201600336 A2 EA201600336 A2 EA 201600336A2
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
diseases
brain diseases
drug
brain
Prior art date
Application number
EA201600336A
Other languages
Russian (ru)
Other versions
EA201600336A3 (en
EA036126B1 (en
Original Assignee
Закрытое Акционерное Общество "Фармфирма "Сотекс"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Закрытое Акционерное Общество "Фармфирма "Сотекс" filed Critical Закрытое Акционерное Общество "Фармфирма "Сотекс"
Publication of EA201600336A2 publication Critical patent/EA201600336A2/en
Publication of EA201600336A3 publication Critical patent/EA201600336A3/en
Publication of EA036126B1 publication Critical patent/EA036126B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к области медицины и химико-фармацевтической промышленности, а именно - к лекарственному средству для лечения заболеваний головного мозга и способу лечения таких заболеваний. Заявлено лекарственное средство, содержащее в качестве активного ингредиента 6-метил-2-этилпиридин-3-ол соль (2S)-2-ацетаминопентандиовой кислоты в фармакологически эффективной дозе, для лечения и/или профилактики заболеваний головного мозга, в частности острых нарушений мозгового кровообращения и энцефалопатии различного генеза, а также способ лечения указанных заболеваний с использованием указанного лекарственного средства. Заявленная группа изобретений позволяет расширить арсенал средств для лечения заболеваний головного мозга, а также усилить фармакологическую активность при одновременном снижении лекарственной нагрузки на пациента.The invention relates to the field of medicine and the pharmaceutical industry, namely to the drug for the treatment of diseases of the brain and the method of treatment of such diseases. Stated drug containing as active ingredient 6-methyl-2-ethylpyridin-3-ol salt (2S) -2-acetaminopentane acid in a pharmacologically effective dose, for the treatment and / or prevention of brain diseases, in particular acute disorders of cerebral circulation and encephalopathy of various origins, as well as a method of treating these diseases using the specified drug. The claimed group of inventions allows you to expand the Arsenal of tools for the treatment of diseases of the brain, as well as to enhance the pharmacological activity while reducing the drug load on the patient.

EA201600336A 2015-03-12 2016-02-25 Method of treating cerebral diseases EA036126B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2015108665A RU2692063C2 (en) 2015-03-12 2015-03-12 Medicinal agent for preventing and treating cerebral diseases and method of treating cerebral diseases

Publications (3)

Publication Number Publication Date
EA201600336A2 true EA201600336A2 (en) 2016-09-30
EA201600336A3 EA201600336A3 (en) 2016-12-30
EA036126B1 EA036126B1 (en) 2020-10-01

Family

ID=53611501

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600336A EA036126B1 (en) 2015-03-12 2016-02-25 Method of treating cerebral diseases

Country Status (2)

Country Link
EA (1) EA036126B1 (en)
RU (1) RU2692063C2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020800B1 (en) * 2012-11-09 2015-01-30 Замертон Холдингс Лимитед Pharmaceutical composition having a neuroprotective, nootropic, antiamnesic effect, and method for preventing and/or treating states associated with cerebral circulation disorders, cerebrovascular and neurodegenerative diseases

Also Published As

Publication number Publication date
RU2015108665A3 (en) 2018-10-24
EA201600336A3 (en) 2016-12-30
RU2692063C2 (en) 2019-06-20
RU2015108665A (en) 2015-07-20
EA036126B1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
EA202090955A1 (en) METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
ECSP18073366A (en) INDOLINE DERIVATIVES SUBSTITUTE AS INHIBITORS OF DENGUE VIRAL REPLICATION
ECSP18073293A (en) INDOLINE DERIVATIVES SUBSTITUTE AS INHIBITORS OF DENGUE VIRAL REPLICATION
BR112015009948A8 (en) Activin-actrii antagonists, uses thereof for treating bone diseases and other disorders, and method for monitoring the effectiveness of treating or preventing a bone disease and other disorders
MX2019012884A (en) Combination therapy.
MX2022003072A (en) Use of pridopidine for treating functional decline.
EA201591535A1 (en) SUBSTITUTED DERIVATIVES OF 3-PHENYL-PROPYLAMINE FOR THE TREATMENT OF OPHTHALMOLOGICAL DISEASES AND DISORDERS
BR112015010396A2 (en) combination therapy
MX2021002321A (en) Novel methods.
EA201991374A1 (en) WATER-SOLUBLE DERIVATIVE OF EPIALLOPRANANOLONE AND ITS APPLICATION
MA39447A1 (en) (s) -pirlindole or its pharmaceutically acceptable salts for use in medicine
UA109359C2 (en) TREATMENT OF SKIN DISEASES AND STATES
MD4763C1 (en) Pharmaceutical composition
BR112018067663A2 (en) sulfamate-derived compounds, processes for their preparation and their uses
EA201600336A2 (en) MEDICINE FOR PREVENTION AND TREATMENT OF BRAIN DISEASES AND METHOD FOR TREATING BRAIN DISEASES
BR112014032264A8 (en) Composition for the treatment or prevention of diseases related to vascular permeability, containing imatinib or a pharmaceutically acceptable salt thereof as an active ingredient
BR112015026484A2 (en) treatment or prevention of noninflammatory neuronal damage from brain trauma and strokes using menthol, linalool and / or icilin
EA202090416A1 (en) METHODS FOR TREATING GASTROPARESIS SYMPTOMS USING A VELUSETRAGA
MX2018013474A (en) Carboxylic acids for early childhood application.
CL2018000085A1 (en) Heteroaryl carbonitriles for the treatment of diseases
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
UA111462C2 (en) Use of (s)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate as active ingredient of pharmaceutical formulations intended for prevention and treatment of impaired vital functions of central nervous system in severe forms of ethanol intoxication
BR112018002433A2 (en) pharmaceutical composition for migraine treatment
AR101227A1 (en) COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN